- Report
- June 2026
- 285 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- April 2026
Global
From €4451EUR$4,900USD£3,842GBP
- Report
- April 2026
Global
From €4451EUR$4,900USD£3,842GBP
- Report
- September 2025
- 100 Pages
Global
From €4451EUR$4,900USD£3,842GBP
- Report
- June 2026
- 265 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 283 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 194 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 285 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 375 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 468 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- November 2025
- 183 Pages
Global
From €4088EUR$4,500USD£3,528GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,520GBP
- Report
- June 2026
- 282 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 380 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 275 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 275 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- June 2026
- 454 Pages
Global
From €5314EUR$5,850USD£4,587GBP
- Report
- October 2025
- 160 Pages
Global
From €3588EUR$3,950USD£3,097GBP
- Report
- October 2025
- 90 Pages
Global
From €4406EUR$4,850USD£3,803GBP
- Report
- January 2025
- 250 Pages
Global
From €4541EUR$4,999USD£3,919GBP

The Hepatitis market is a subset of the larger Hepatology market, which focuses on the diagnosis, treatment, and prevention of liver diseases. Hepatitis is a viral infection that can cause inflammation of the liver, and can be caused by a variety of viruses, including hepatitis A, B, C, D, and E. Treatment for hepatitis can include antiviral medications, immunosuppressants, and interferon therapy. Vaccines are also available to prevent hepatitis A and B.
The Hepatitis market is a growing field, with a focus on developing new treatments and therapies to improve patient outcomes. Companies in the market include Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Novartis. Show Less Read more